UK-based GlaxoSmithKline PLC (GB:GSK) has won the latest U.S. trial concerning its heartburn drug Zantac (ranitidine), amid litigation over alleged cancer risks. The Florida State Court ruled in ...

Twelve days after GSK secured a key win in Florida, with a state court tossing expert testimony on the cancer-causing ...

GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn ...

Zamboni is expected to say the 'Tanner study - which was not submitted to the FDA until 2019 - provides evidence that GSK knew about Zantac's potential health impacts, but failed to make the ...

(Reuters) – GSK won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman’s illness, a ...